CHM 1101 GBM Abstract Accepted for ASCO 2023 Presentation

- Acceptance of CHM 1101 abstract for presentation at premier oncology meeting, Annual Meeting of the American Society of Clinical Oncology (ASCO)
- Abstract will highlight the clinical trial design and objectives for new Phase 1B CHM 1101 clinical trial

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that from more than 6,500 abstracts submitted, a CHM 1101 abstract was selected for presentation at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from 2-6 June 2023 in Chicago, Illinois.

Chimeric is pleased that ASCO has selected the abstract for presentation as it highlights the clinical trial design and objectives of Chimeric’s new multi-site Phase 1B clinical trial with CHM 1101 in patients with recurrent or progressive Glioblastoma (GBM).

Details of the abstract presentation are as follows:

**Section:** Central Nervous System Tumors  
**Abstract #:** 418236  
**Title:** Phase 1b multicenter study to evaluate CHM 1101 in patients with recurrent or progressive glioblastoma  
**Session Date and Time:** 3 June 2023, 1:15 PM-4:15 PM

---

**About CHM 1101:**

CHM 1101 (CLTX CAR T) is a first and potentially best in class CAR T therapy that has the potential to address the high unmet medical need of patients with recurrent or progressive glioblastoma. Research to develop the intellectual property covering this CAR T cell therapy took place at City of Hope.

CLTX CAR T cells uniquely utilizes chlorotoxin (CLTX), a peptide component of scorpion venom, as the tumour-targeting component of the chimeric antigen receptor (CAR). CLTX and CLTX CAR
T cells have been shown in preclinical models to bind more broadly and specifically to GBM cells than other targeting domains like EGFR, HER-2 or IL-13.

In preclinical models, CLTX CAR T cells also demonstrated potent antitumor activity against glioblastoma while not exhibiting any off-tumor recognition of normal human cells and tissues, indicating a potentially optimal safety and efficacy profile.

CHM 1101 is currently being studied in a phase 1A clinical trial in recurrent / progressive glioblastoma. Initial positive data has been presented on patients treated in the first two dose levels of the trial.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent / progressive glioblastoma. Initial positive data has been presented on patients treated in the first two dose levels of the trial.

CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer demonstrating complete eradication of tumors in 7 types of cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in gastrointestinal and neuroendocrine tumours.

CHM 0201 (CORE-NK platform) is a clinically validated, off the shelf natural killer (NK) cell platform. Data from the complete phase 1 clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, an additional Phase1B clinical trial investigating CHM 0201 in combination with IL2 and Vactosertib is now underway. From the CHM 0201 platform, Chimeric has initiated development of new next generation NK and CAR NK assets with plans for phase 1 clinical trials in solid tumours and blood cancers.
Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

CONTACT

Investors
Jennifer Chow  
Chief Executive Officer and Managing Director  
Chimeric Therapeutics  
T: + 1 9087238387  
E: jchow@chimerictherapeutics.com  
W: www.chimerictherapeutics.com

Paul Hopper  
Executive Chairman  
Chimeric Therapeutics  
T: + 61 406 671 515  
E: paulhopper@lifescienceportfolio.com

Media
Matthew Wright  
NWR Communications  
P: +61 451 896 420  
E: matt@nwrcommunications.com.au